Cue Biopharma reported a net loss of $153.1 million for the quarter ended June 30, 2026, driven by one-time non-cash losses and expenses related to its license agreement with Ascendant. Revenue increased to $7.9 million from collaboration milestones. The company completed a $50 million private placement financing subsequent to the quarter end to support clinical development. Key operational highlights include an IND submission for CUE-221 in food allergies, anticipated Phase 2 data readout by late Q3 2026, and leadership additions including new CMO Dr. Dominic Borie and CFO James M. Ahlers. Cue Biopharma is a clinical-stage biopharmaceutical company developing therapies for immune-mediated diseases.

Cue Biopharma appointed James Ahlers as its new Chief Financial Officer, effective July 30, 2026. The executive employment agreement provides an annualized base salary of $450,000 and a discretionary bonus target of up to 45% of base salary. Upon appointment, Mr. Ahlers received an initial grant of nonstatutory stock options for 51,000 shares at an exercise price of $30.40 per share and restricted stock units for 25,500 shares, both vesting quarterly over four years. The agreement includes severance provisions equal to nine months of base salary plus target bonus in the event of a qualifying termination. Cue Biopharma operates in the biotechnology industry, focusing on drug discovery and development.

Cue Biopharma, Inc. entered into a Securities Purchase Agreement on July 9, 2026, to issue and sell 1,418,071 shares of common stock at $33.21 per share and 87,500 pre-funded warrants at $33.209 per warrant for gross proceeds of approximately $50.0 million. The company intends to use the net proceeds to fund clinical development and general corporate purposes. Cue Biopharma, Inc. is a biopharmaceutical company focused on developing clinical-stage product candidates.